Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Commodities
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
SCYNEXIS Inc
SCYX
Healthcare
SCYNEXIS, Inc. is a biotechnology company. The Company is developing its lead product candidate, ibrexafungerp, as a broad-spectrum, intravenous (IV)/oral agent for multiple fungal indications in both the community and hospital settings. Its Ibrexafungerp has demonstrated activity against a large collection of medically relevant strains of Candida and Aspergillus genera, including multidrug...
-resistant strains, as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera. The Company has received approval from the United States Food and Drug Administration (FDA) for the New Drug Application (NDA) for BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC, also known as vaginal yeast infection), and for the reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC), respectively.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:SCYX)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
Next
(31)
•••
dmacd
X
Post by
dmacd
on Sep 17, 2021 5:08pm
Stop Raising Dilutive Funds
Show some progress.before another capital raise. No focus on SP. Winning losers .. grrrrr.
(31)
•••
dmacd
X
Comment by
dmacd
on Aug 17, 2021 2:35pm
RE:RE:RE:Drug just got approved! :)
Wow. These biopharma stocks are truly in show me stage for valuation. Great opportunity for those with high conviction (like me) to load up way more than you thought you could. Sales will start slow
...more
(31)
•••
dmacd
X
Comment by
dmacd
on Jul 30, 2021 12:34pm
RE:Short Interest...
Shorters might have their way for now but once sales start to roll out then they will pay up. There cannot be a lot of downside to warrant taking on the risk of upside on positive roll out news. The
...more
(119)
•••
JonathanJSmith
X
Post by
JonathanJSmith
on Jun 25, 2021 10:21am
Short Interest...
Crazy high short interest here ( > 3.6mm shares short). I guess that's why the stock went down upon approval. I'm waiting for the EMEA contract to be finalized; with luck it'll be
...more
(119)
•••
JonathanJSmith
X
Comment by
JonathanJSmith
on Jun 02, 2021 3:58pm
RE:RE:Drug just got approved! :)
Yeah, I wasn't expecting this kind of reaction either. The next few weeks will tell the tale; the approval information needs to be absorbed. Based on the CC today, I inferred that an EMEA
...more
(0)
•••
Kipper22
X
Comment by
Kipper22
on Jun 02, 2021 11:06am
RE:Drug just got approved! :)
Seriously!? Approved and it goes down... Wtf
(119)
•••
JonathanJSmith
X
Post by
JonathanJSmith
on Jun 02, 2021 7:39am
Drug just got approved! :)
https://finance.yahoo.com/news/scynexis-announces-fda-approval-brexafemme-113000221.html Cheers, JJ
(119)
•••
JonathanJSmith
X
Comment by
JonathanJSmith
on Jun 02, 2021 7:26am
RE:RE:2 Weeks Left...
Yeah, everyone's in waiting mode. I think the company has 24 hours to release material information - assuming they've received some. Personally, based on data the drug should be approved. My
...more
(0)
•••
Kipper22
X
Comment by
Kipper22
on Jun 02, 2021 4:58am
RE:2 Weeks Left...
Wasn't the FDA supposed to deliver their verdict yesterday?
(119)
•••
JonathanJSmith
X
Post by
JonathanJSmith
on May 17, 2021 11:23am
2 Weeks Left...
Only two weeks before a decision is made on Ibrexa. Hmmm, could be quite a windfall if approved. Time to roll the dice! ;) Cheers, JJ
(119)
•••
JonathanJSmith
X
Comment by
JonathanJSmith
on Apr 27, 2021 10:26am
RE:RE:RE:scyx needs to find financial backing
Dude, They have enough money to last until 2023 ($93MM) according to recent filings. Currently, they have ~20MM shares outstanding; fully diluted, this number is ~40MM however, that includes another
...more
(119)
•••
JonathanJSmith
X
Post by
JonathanJSmith
on Apr 27, 2021 10:18am
Time for options w/upcoming PDUFA date?
Which June call should I buy? For fun I ran the numbers assuming a $12,000 investment w/commissions ignored, and here's what I got*: -------------------------------------------------- 1) Strike
...more
(31)
•••
dmacd
X
Comment by
dmacd
on Apr 01, 2021 2:18pm
RE:RE:scyx needs to find financial backing
I have seen some good moves lately by management. New guy from viveve seems to have learned his lesson. Dilution needs to stop now. Enough already. I doubled down recently with a 5x target by 2023
...more
(31)
•••
dmacd
X
Comment by
dmacd
on Jun 26, 2020 10:24pm
RE:scyx needs to find financial backing
New marketing guy was a disaster at Viveve. He spent way more than his team earned and perpetually under delivered. I am puzzled by this appointment.
(198)
•••
Tcheck
X
Post by
Tcheck
on Mar 11, 2020 3:51pm
scyx needs to find financial backing
it will stop our headache
Prev
1
2
3
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Want to know which Canadian silver exchange traded funds on the Toronto Stock Exchange are the best?
On a Mission to Make Bitcoin Less Risky, More Accessible and More Inclusive for Investors
Stunning Drill Results at Historic Copper Mine in Ontario with 14.8% Copper over 2.45 Metres
AI Beyond Hype: Real-world Applications and Possibilities